ClinicalTrials.gg
CompletedNCT00916357Updated Aug 18, 2014Results posted

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

A Phase 2 interventional study of Humalog and Humulin-R in Diabetes Mellitus, Type 2, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-08-18.

Sponsored by Halozyme Therapeutics · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 2.

Enrollment
33rd of 36
23 · median 127
Started
2009
with 1 other
Phase 2
2 of 36
none open now
Registered
12th of 36
by date
Lead sponsor
2 of 36
Halozyme Therapeutics

Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, this one is the 33rd largest by enrollment, is one of 2 that started in 2009, is one of 2 in phase 2, and was the 12th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This is a single-center, Phase 2, randomized, double-blind, 3-way crossover meal study in participants with Type 2 Diabetes Mellitus (T2DM) to determine the optimum dose and compare the pharmacokinetics (PK) and postprandial glycemic response of Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), and Humulin-R + rHuPH20 administered subcutaneously.

Read the detailed description

This study design was chosen to assess the differences between pharmacokinetic (PK) and pharmacodynamic (PD) parameters, including postprandial glycemic response, of Humalog + recombinant human hyaluronidase PH20 (rHuPH20), Humalog alone, and Humulin-R + rHuPH20 at optimal doses following a liquid meal.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • recombinant human hyaluronidase PH20 (rHuPH20)
  • Insulin lispro
  • Regular human insulin
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of age 18 to 70 years, inclusive
  • Participants with Type 2 diabetes mellitus (T2DM) per World Health Organization criteria treated with basal and/or bolus insulin for ≥12 months.
  • (BMI) between 18 to 45 kilograms per square meter (kg/m\^2), inclusive
  • Glycosylated (HbA1c) ≤10%
  • Current treatment with insulin ≥60 Units/day (U/d)
  • A participant taking oral hypoglycemic agents must be on a stable dose for >8 weeks with the exception of thiazolidinediones (TZD), which should be >12 weeks.
  • Total body weight >65 kilograms (kg) (143 pounds [lb]) for men and >46 kg (101 lb) for women
  • Vital signs (blood pressure [BP], pulse rate, and body temperature) within normal range or, if out of range, assessed by the Investigator as not (NCS)
  • Participants should be in good general health based on medical history and physical examination without medical conditions that might prevent the completion of study drug injections and assessments in this protocol
  • Decision making capacity and willingness to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures including adequate venous access.
  • Signed and written Internal Review Board-approved

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to any components of any of the study drugs in this study
  • Previous enrollment in this study
  • A participant who has proliferative retinopathy, proliferative maculopathy, and/or severe neuropathy (in particular, autonomic neuropathy) as judged by the Investigator
  • As judged by the Investigator, active disease of the gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on [ECG] and [NYHA] Class III/IV heart disease), hepatic, neurological, renal, genitourinary, or hematological systems
  • As judged by the Investigator, uncontrolled hypertension (diastolic BP ≥100 millimeters of mercury [mmHg] and/or systolic BP ≥160 mmHg after 5 minutes in the supine position).
  • As judged by the Investigator, clinically significant findings in routine laboratory data (anemia with hematocrit less than 33% at screening is specifically exclusionary)
  • Positive (HIV) antibody test, (anti-HBsAg), or (anti-HCV) antibody test
  • Current addiction to alcohol or substances of abuse as determined by the Investigator
  • Known use of drugs (other than oral hypoglycemic agents) that may interfere with the interpretation of study results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia
  • Recurrent major hypoglycemia or hypoglycemic unawareness as determined by the Investigator
  • Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation in this study
  • Symptomatic gastroparesis
  • Donation of blood in excess of 500 milliliters (mL) within 56 days before dosing
  • Use of any drug or device 30 days before enrollment in this study
  • Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate measures (adequate contraceptive measures consist of sterilization, intra-uterine device [IUD], oral or injectable contraceptives, barrier methods, or remaining abstinent)
  • Any condition (intrinsic or extrinsic) that, in the judgment of the Investigator, will interfere with study participation or evaluation of data
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Active comparator
    Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20

    A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout period), followed by a SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3 to 14 day washout period.

    Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20

    A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.

    Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20

    A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase PH20(rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.

    Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog

    A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog following a 3- to 14-day washout period.

    Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20

    A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.

    Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog

    A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog alone following a 3- to 14-day washout period.

    Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

Interventions

06

What researchers measure

Primary outcomes

  1. Postprandial Glucose (PPG) Excursion Following a Liquid Meal

    Postprandial glucose (PPG) values in participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal are reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least square mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.

    Time frame: Predose up to 480 minutes after study drug injection

Secondary outcomes

  1. Maximum Serum Insulin Concentration (Cmax)

    Maximum serum insulin concentration (Cmax) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

    Time frame: Predose up to 480 minutes after study drug injection

  2. Time To Maximum Serum Insulin Concentration (Tmax)

    Time to maximum serum insulin concentration (Tmax) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

    Time frame: Predose up to 480 minutes after study drug injection

  3. Time to Early 50% Maximum Serum Insulin Concentration (Early[t50%])

    Time to early 50% maximum serum insulin concentration (early\[t50%\]) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, and 120 minutes after injection of each study drug.

    Time frame: Predose up to 120 minutes after study drug injection

  4. Time to Late 50% Maximum Serum Insulin Concentration (Late[t50%])

    Time to late 50% maximum serum insulin concentration (late\[t50%\]) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

    Time frame: Predose up to 480 minutes after study drug injection

  5. Mean Residence Time From Time 0 to the End of Blood Sampling (MRT[Last])

    Mean residence time from time 0 to the end of blood sampling (MRT\[last\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

    Time frame: Predose up to 480 minutes after study drug injection

  6. Area Under the Concentration Time-Curve for Serum Insulin From Time 0 to the End of Blood Sampling (AUC[Last])

    Area under the concentration time-curve for serum insulin from time 0 to the end of blood sampling (AUC\[last\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 during a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least squares mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.

    Time frame: Predose up to 480 minutes after study drug injection

  7. Area Under the Time-Concentration Curve for Blood Glucose (AUC[BG])

    Area under the time-concentration curve for blood glucose (AUC\[BG\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), and Humulin-R + rHuPH20 following a liquid meal is reported. AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 160 milligrams per deciliter (mg/dL) or 140 mg/dL, or lower than 70 mg/dL within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least squares mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.

    Time frame: Predose up to 480 minutes after study drug injection

  8. Minimum Postprandial Glucose (PPG)

    Minimum postprandial glucose (PPG) in participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

    Time frame: Predose up to 480 minutes after study drug injection

  9. Percentage of Participants Without Hypoglycemia

    Percentage of participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 who did not experience hypoglycemia following a liquid meal is reported. Hypoglycemia was defined as any blood glucose values lower than 70 milligrams per deciliter (mg/dL) or symptoms of hypoglycemia responding to treatment with glucose. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

    Time frame: Predose up to 480 minutes after study drug injection

  10. Time to Percentage of Insulin Exposure (as Measured by Area Under the Curve [AUC])

    Time to percentage of exposure to insulin, as measured by area under the curve (AUC), following a liquid meal for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

    Time frame: Predose up to 480 minutes following after injection of study drug

07

Results

Posted Aug 18, 2014

Participant flow

Period 1
Participant flow — Period 1
MilestoneHumalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then HumalogHumulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog
Started444434
Received at least 1 dose of study drug444434
Completed344434
Not completed100000
Withdrew: Withdrawal by subject100000
Washout (3 to 14 Days)
Participant flow — Washout (3 to 14 Days)
MilestoneHumalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then HumalogHumulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog
Started344434
Completed344434
Not completed000000
Period 2
Participant flow — Period 2
MilestoneHumalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then HumalogHumulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog
Started344434
Completed344334
Not completed000100
Withdrew: Weight loss > 3 kilograms (kg)000100
Washout (3 to 14 Days)
Participant flow — Washout (3 to 14 Days)
MilestoneHumalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then HumalogHumulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog
Started344334
Completed344334
Not completed000000
Period 3
Participant flow — Period 3
MilestoneHumalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then HumalogHumulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog
Started344334
Completed344334
Not completed000000

Outcome measures

PrimaryPostprandial Glucose (PPG) Excursion Following a Liquid Meal

Postprandial glucose (PPG) values in participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal are reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least square mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.

Time frame:
Predose up to 480 minutes after study drug injection
Reported as:
Least squares mean · Milligrams per deciliter (mg/dL)
Postprandial Glucose (PPG) Excursion Following a Liquid Meal
Milligrams per deciliter (mg/dL)Humalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
60-minute PPG162.71 ± 32.28144.67 ± 28.08169.38 ± 28.64
90-minute PPG166.05 ± 34.53143.62 ± 30.75166.71 ± 33.83
120-minute PPG159.10 ± 30.73138.24 ± 32.34159.90 ± 39.56
CBGMax(0-4hr)177.81 ± 33.46165.38 ± 21.39181.62 ± 31.61
Statistical analysis
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0034 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.2600 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated measures Analysis of Variance · p = 0.0001 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0039 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.9300 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0031 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0190 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.9200 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0150 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0950 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.6000 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0310 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
SecondaryMaximum Serum Insulin Concentration (Cmax)

Maximum serum insulin concentration (Cmax) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

Time frame:
Predose up to 480 minutes after study drug injection
Reported as:
Mean · Picomoles per liter (pm/L)
Maximum Serum Insulin Concentration (Cmax)
Picomoles per liter (pm/L)Humalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
Maximum Serum Insulin Concentration (Cmax)3329.49 ± 1090.025661.92 ± 1307.753011.56 ± 962.31
Statistical analysis
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.1800 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
SecondaryTime To Maximum Serum Insulin Concentration (Tmax)

Time to maximum serum insulin concentration (Tmax) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

Time frame:
Predose up to 480 minutes after study drug injection
Reported as:
Mean · Minutes (min)
Time To Maximum Serum Insulin Concentration (Tmax)
Minutes (min)Humalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
Time To Maximum Serum Insulin Concentration (Tmax)74.29 ± 36.2743.10 ± 16.0181.67 ± 40.26
Statistical analysis
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0045 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.4800 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0006 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
SecondaryTime to Early 50% Maximum Serum Insulin Concentration (Early[t50%])

Time to early 50% maximum serum insulin concentration (early\[t50%\]) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, and 120 minutes after injection of each study drug.

Time frame:
Predose up to 120 minutes after study drug injection
Reported as:
Mean · Minutes (min)
Time to Early 50% Maximum Serum Insulin Concentration (Early[t50%])
Minutes (min)Humalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
Time to Early 50% Maximum Serum Insulin Concentration (Early[t50%])27.02 ± 8.6718.71 ± 5.8021.46 ± 8.19
Statistical analysis
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0016 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.1000 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
SecondaryTime to Late 50% Maximum Serum Insulin Concentration (Late[t50%])

Time to late 50% maximum serum insulin concentration (late\[t50%\]) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

Time frame:
Predose up to 480 minutes after study drug injection
Reported as:
Mean · Minutes (min)
Time to Late 50% Maximum Serum Insulin Concentration (Late[t50%])
Minutes (min)Humalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
Time to Late 50% Maximum Serum Insulin Concentration (Late[t50%])206.86 ± 41.66123.93 ± 44.59220.33 ± 51.98
Statistical analysis
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison of Humalog alone + Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.3000 (Treatment comparison for Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
SecondaryMean Residence Time From Time 0 to the End of Blood Sampling (MRT[Last])

Mean residence time from time 0 to the end of blood sampling (MRT\[last\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

Time frame:
Predose up to 480 minutes after study drug injection
Reported as:
Mean · Minutes (min)
Mean Residence Time From Time 0 to the End of Blood Sampling (MRT[Last])
Minutes (min)Humalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
Mean Residence Time From Time 0 to the End of Blood Sampling (MRT[Last])148.79 ± 22.46108.23 ± 20.56150.24 ± 27.32
Statistical analysis
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.7700 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
SecondaryArea Under the Concentration Time-Curve for Serum Insulin From Time 0 to the End of Blood Sampling (AUC[Last])

Area under the concentration time-curve for serum insulin from time 0 to the end of blood sampling (AUC\[last\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 during a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least squares mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.

Time frame:
Predose up to 480 minutes after study drug injection
Reported as:
Least squares mean · Minutes * picomoles /1000 (min*pm/1000)
Area Under the Concentration Time-Curve for Serum Insulin From Time 0 to the End of Blood Sampling (AUC[Last])
Minutes * picomoles /1000 (min*pm/1000)Humalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
Area Under the Concentration Time-Curve for Serum Insulin From Time 0 to the End of Blood Sampling (AUC[Last])578.67 ± 144.66668.33 ± 146.52571.42 ± 132.04
Statistical analysis
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0100 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.8200 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.0056 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
SecondaryArea Under the Time-Concentration Curve for Blood Glucose (AUC[BG])

Area under the time-concentration curve for blood glucose (AUC\[BG\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), and Humulin-R + rHuPH20 following a liquid meal is reported. AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 160 milligrams per deciliter (mg/dL) or 140 mg/dL, or lower than 70 mg/dL within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least squares mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.

Time frame:
Predose up to 480 minutes after study drug injection
Reported as:
Least squares mean · Milligrams per deciliter * minutes
Area Under the Time-Concentration Curve for Blood Glucose (AUC[BG])
Milligrams per deciliter * minutesHumalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
AUC(BG) >160 mg/dL2017.46 ± 2811.82722.82 ± 1030.522509.65 ± 3332.36
AUC(BG) >140 mg/dL4233.71 ± 4383.352696.54 ± 2548.034905.92 ± 4829.71
AUC(BG) <70 mg/dL571.20 ± 850.07197.00 ± 480.75408.50 ± 602.29
Statistical analysis
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.064 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.47 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.012 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.099 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.46 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.020 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.13 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.41 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.46 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
SecondaryMinimum Postprandial Glucose (PPG)

Minimum postprandial glucose (PPG) in participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

Time frame:
Predose up to 480 minutes after study drug injection
Reported as:
Mean · Milligrams per deciliter (mg/dL)
Minimum Postprandial Glucose (PPG)
Milligrams per deciliter (mg/dL)Humalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
Minimum Postprandial Glucose (PPG)76.38 ± 22.5888.52 ± 27.3775.62 ± 20.15
Statistical analysis
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.016 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.8800 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.011 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
SecondaryPercentage of Participants Without Hypoglycemia

Percentage of participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 who did not experience hypoglycemia following a liquid meal is reported. Hypoglycemia was defined as any blood glucose values lower than 70 milligrams per deciliter (mg/dL) or symptoms of hypoglycemia responding to treatment with glucose. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

Time frame:
Predose up to 480 minutes after study drug injection
Reported as:
Number · Percentage of participants
Percentage of Participants Without Hypoglycemia
Percentage of participantsHumalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
Percentage of Participants Without Hypoglycemia81.071.471.4
SecondaryTime to Percentage of Insulin Exposure (as Measured by Area Under the Curve [AUC])

Time to percentage of exposure to insulin, as measured by area under the curve (AUC), following a liquid meal for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.

Time frame:
Predose up to 480 minutes following after injection of study drug
Reported as:
Mean · Minutes (min)
Time to Percentage of Insulin Exposure (as Measured by Area Under the Curve [AUC])
Minutes (min)Humalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
Time to 10% Insulin Exposure46.05 ± 8.9830.49 ± 7.1343.41 ± 10.21
Time to 50% Insulin Exposure135.73 ± 21.1894.49 ± 20.06137.52 ± 27.35
Statistical analysis
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison of Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.1800 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)
  • Humalog Alone vs Humalog + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison for Humalog alone and Humalog + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog Alone vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = 0.7200 (Treatment comparison of Humalog alone and Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20).)
  • Humalog + rHuPH20 vs Humulin-R + rHuPH20 · Repeated Measures Analysis of Variance · p = <0.0001 (Treatment comparison of Humalog + recombinant human hyaluronidase PH20 (rHuPH20) and Humulin-R + rHuPH20.)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Humalog Alone—0/22 (0%)11/22 (50%)
Humalog + rHuPH20—1/22 (4.5%)5/22 (22.7%)
Humulin-R + rHuPH20—0/22 (0%)10/22 (45.5%)
Most frequent serious events
Most frequent serious events
EventHumalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
UrosepsisInfections and infestations0/221/220/22
Pyelonephritis acuteInfections and infestations0/221/220/22
DehydrationMetabolism and nutrition disorders0/221/220/22
NephrolithiasisRenal and urinary disorders0/221/220/22
Renal colicRenal and urinary disorders0/221/220/22
Ureteric obstructionRenal and urinary disorders0/221/220/22
Most frequent other events
Showing 10 of 26
Most frequent other events
EventHumalog AloneHumalog + rHuPH20Humulin-R + rHuPH20
HeadacheNervous system disorders3/220/222/22
NauseaGastrointestinal disorders2/221/221/22
Upper respiratory tract infectionInfections and infestations0/220/222/22
Limb injuryInjury, poisoning and procedural complications0/221/220/22
Skin lacerationInjury, poisoning and procedural complications0/221/220/22
Injection site painGeneral disorders0/221/221/22
DiarrhoeaGastrointestinal disorders1/221/220/22
Abdominal painGastrointestinal disorders1/221/220/22
Abdominal pain upperGastrointestinal disorders0/220/221/22
InfluenzaInfections and infestations1/220/220/22

Baseline characteristics

Participants who received at least 1 dose of Humalog, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 during dose-finding (DV) visits or experimental (data gathering) visits.

Age, Continuous
Age, Continuous(Years (yr))Overall Study
Mean52.2 ± 8.07
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female9
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino9
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American4
White17
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Study
United States23
08

Study locations

1 site
  • Profil Institute for Clinical Research, Inc.
    Chula Vista, California 91911, United States
09

References and documents

Publications

  • Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther. 2012 Mar;14(3):218-24. doi: 10.1089/dia.2011.0117. Epub 2011 Dec 2. PubMed 22136324 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2009
First posted
Jun 9, 2009
Start
Jul 2009
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Aug 18, 2014
Last update
Aug 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00916357
Responsible party
Sponsor
First posted
Jun 9, 2009
Start date
Jul 2009
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Aug 18, 2014
Last update
Aug 18, 2014

Study contacts

Marcus Hompesch, M.D.
principal investigator · Profil Institute for Clinical Research, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Lispro · Insulin, Regular, Human · Hyaluronidase (human recombinant)

Start the discussion